Search
Haemonetics Corp
HAEAdd to Watchlist
56.290USD
-0.850-1.49%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
2.64BMarket Cap
15.46P/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-1.49%
5 Days
+2.12%
1 Month
-6.36%
6 Months
-23.40%
Year to Date
-29.77%
1 Year
-19.94%
TradingKey Stock Score of Haemonetics Corp
Currency: USD Updated: 2026-05-15Key Insights
Haemonetics Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 82.22.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Haemonetics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Haemonetics Corp Highlights
StrengthsRisks
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 16.44% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.36B.
Undervalued
The company’s latest PE is 15.46, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 58.91M shares, increasing 1.11% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 161.00 shares of this stock.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
82.222
Target Price
+44.22%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Haemonetics Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Haemonetics Corp Info
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.
Ticker SymbolHAE
CompanyHaemonetics Corp
CEOSimon (Christopher A)
Websitehttps://www.haemonetics.com
Related Instruments
-1.32%
-2.23%
-1.62%
-0.49%
-1.30%
+0.41%
-1.57%
-2.22%
-1.05%
-1.04%
-1.59%
-3.29%
-1.06%
+0.04%
-0.76%
-0.71%
+1.31%
-1.21%
-1.39%
-0.56%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
78001.660
-229.340 (-0.29%)
422.240
-21.060 (-4.75%)
